SIBN

SANTA CLARA, Calif., June 04, 2026 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), the global leader in developing procedural solutions to address clinical challenges associated with compromised bone, today announced that the company will be participating in the upcoming 2026 Truist Securities MedTech Conference in Boston, MA. Management will be hosting a fireside chat on Tuesday, June 16, 2026, at 5:40 a.m. Pacific Time/ 8:40 a.m. Eastern Time.

Si-Bone (SIBN) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

The average of price targets set by Wall Street analysts indicates a potential upside of 71.1% in Si-Bone (SIBN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Gazprom Neft , ​the oil arm ‌of Russia's energy giant ​Gazprom , ​said on Friday its ⁠first-quarter ​net profit declined ​by 3.5% year-on-year to 95.8 ​billion roubles ($1.35 ​billion).

The consensus price target hints at a 65.3% upside potential for Si-Bone (SIBN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

SI-BONE, Inc. (SIBN) Presents at Bank of America Global Healthcare Conference 2026 Transcript

SI-BONE, Inc. (SIBN) Q1 2026 Earnings Call Transcript

SiBone NASDAQ: SIBN raised its full-year 2026 outlook after reporting double-digit revenue growth in the first quarter, with management pointing to new product launches, expanding physician adoption, international momentum and a proposed Medicare reimbursement change as key drivers for the year ahead.

Si-Bone (SIBN) came out with a quarterly loss of $0.1 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to a loss of $0.15 per share a year ago.

Delivered ~11% worldwide revenue growth, record physician engagement and ~440% improvement in adjusted EBITDA Delivered ~11% worldwide revenue growth, record physician engagement and ~440% improvement in adjusted EBITDA